TG Therapeutics

Valuation Analysis

About the Company

TG Therapeutics en bref

TG Therapeutics (TGTX) is currently trading at 45,11 € with a market capitalization of 6,9 Md €. The trailing P/E ratio stands at 18.19x, with a forward P/E of 15.86x. The 52-week range spans from 21,92 € to 51,41 €; the current price is 12.3% below the yearly high. Year-over-year revenue growth stands at +69.6%. The net profit margin stands at 65.95%.

💰 Dividende

TG Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

7 analystes évaluent TG Therapeutics (TGTX) au consensus : Achat Fort. L'objectif de cours moyen est de 59,33 €, soit un potentiel de +31.52% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 17,34 € à 74,56 €.

TG Therapeutics : la thèse d'investissement en détail

TG Therapeutics (TGTX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 69.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 83.05%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 112.6% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

Le scénario baissier

Short interest sits at 28.97% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The EV/EBITDA multiple of 50.9x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 15.86x is meaningfully below the trailing 18.19x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 31.52% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to above-average price swings, elevated short interest (28.97%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy TG Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.